Every 10-Q that Eli Lilly and Company (LLY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LLY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LLY filings page.
Eli Lilly posted very strong Q1 2026 results, with revenue of $19.8 billion, up 56% from a year earlier, and diluted EPS of $8.26 versus $3.06. Net income rose to $7.4 billion, a 168% increase.
Growth was driven by incretin medicines. Mounjaro generated $8.7 billion in revenue and Zepbound $4.2 billion, and together with other cardiometabolic drugs they made up 65% of total revenue. International sales nearly doubled, helped by Mounjaro launches, though prices fell in some markets such as China.
Research and development spending increased 28% to $3.5 billion as Lilly advanced an extensive late-stage pipeline, while acquired in-process R&D charges dropped sharply. Operating cash flow reached $5.3 billion, funding heavy capital investment, the $1.1 billion Ventyx acquisition, $2.3 billion of share repurchases, and $1.5 billion in dividends. Management highlights rising pricing and reimbursement pressure, including U.S. drug pricing reforms and new agreements that lower certain prices, as key risks alongside the company’s growing reliance on incretin therapies.
Eli Lilly (LLY) reported sharply higher Q3 results. Revenue rose to $17,600.8 million from $11,439.1 million a year ago, driven by cardiometabolic medicines. Net income increased to $5,582.5 million from $970.3 million, with diluted EPS of $6.21 versus $1.07.
Growth was led by Mounjaro ($6,515.1 million total) and Zepbound ($3,588.1 million), lifting total cardiometabolic health revenue to $13,177.9 million. Oncology contributed $2,407.6 million, and immunology $1,362.4 million. Operating cash flow for the nine months reached $13,588.4 million. Cash and equivalents were $9,791.9 million, while long‑term debt was $40,873.6 million. The company recognized $655.7 million of acquired IPR&D and $364.9 million of special charges in the quarter.
Lilly completed the Verve Therapeutics acquisition for $549.4 million net of cash, with a contingent value right of up to $300.0 million. Pre‑launch inventories were $952.3 million, primarily for orforglipron. As of September 30, $12.40 billion remained under the $15.00 billion share repurchase authorization. Shares outstanding were 945,383,757 as of October 27, 2025.
Eli Lilly (LLY) posted another record quarter. Q2-25 revenue rose 38 % YoY to $15.56 bn, driven by cardiometabolic products (Mounjaro +68 % to $5.20 bn; first-year Zepbound $3.38 bn). Oncology added $2.41 bn (+12 %).
Profitability surged. Net income nearly doubled to $5.66 bn; diluted EPS jumped 92 % to $6.29. Six-month EPS is $9.35 (+62 %). Operating margin expanded as revenue growth outpaced increases in R&D (↑23 %) and SG&A (↑30 %). No special charges occurred this quarter versus $435 m last year.
Balance-sheet trends. Total assets grew to $100.9 bn (-year-end 24: $78.7 bn) mainly from higher receivables and a $3.4 bn inventory build to support GLP-1 demand. Debt increased to $39.9 bn (-year-end: $33.6 bn) after $6.46 bn of new issuances. Cash & equivalents held steady at $3.38 bn; operating cash flow more than doubled to $4.75 bn YTD.
Capital returns & pipeline. Dividend lifted to $3.00/sh (prior-year $2.60). $13.11 bn remains on the $15 bn buyback plan. Business development continues: closed $925 m Wisconsin injectables plant (May) and, post-quarter, announced up to $2.3 bn acquisitions of Verve (cardiovascular gene therapy) and SiteOne (pain).
Outlook signals. U.S. revenue accounted for 69 % of sales; Europe grew 83 % YoY. Management highlights demand but warns of pricing, manufacturing and regulatory risks. No updated guidance included in the excerpt.